{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:25:48Z","timestamp":1782390348535,"version":"3.54.5"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2110819"],"award-info":[{"award-number":["W81XWH2110819"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["VA CSR&D IK2 CX-002531"],"award-info":[{"award-number":["VA CSR&D IK2 CX-002531"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>While immunotherapy has been widely adopted for the treatment of melanoma, its application in patients with complex comorbidities remains challenging. This review explores evidence on the efficacy, safety, and special considerations for the use of immunotherapy in patients with altered immune systems, including patients with human immunodeficiency virus (HIV), tuberculosis, solid organ or hematopoietic cell transplantation, autoimmune diseases, and pregnant women. Despite data emphasizing the feasibility of immunotherapy treatment in these populations, standardized management algorithms are lacking. Future research should consider either including these patients in prospective trials or attempting to collect data via registries to provide more clarity on the management of immunologically vulnerable patients with melanoma.<\/jats:p>","DOI":"10.1007\/s12325-025-03453-8","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T17:28:14Z","timestamp":1767029294000},"page":"551-566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy for Melanoma in Patients with Altered Immune Systems: Unique Challenges and Clinical Considerations"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3347-0629","authenticated-orcid":false,"given":"Bryan L.","family":"Peacker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1960-3296","authenticated-orcid":false,"given":"Rebecca I.","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"3453_CR1","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398:1002\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(21)01206-X.","journal-title":"Lancet"},{"key":"3453_CR2","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS. CAR T\u00a0cells and T-cell therapies for cancer: a translational science review. JAMA. 2024;332:1924\u201335. https:\/\/doi.org\/10.1001\/jama.2024.19462.","journal-title":"JAMA"},{"key":"3453_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","volume":"36","author":"T Amaral","year":"2025","unstructured":"Amaral T, Ottaviano M, Arance A, et al. Cutaneous melanoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36:10\u201330. https:\/\/doi.org\/10.1016\/j.annonc.2024.11.006.","journal-title":"Ann Oncol"},{"key":"3453_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095096","volume":"9","author":"CM Olsen","year":"2014","unstructured":"Olsen CM, Knight LL, Green AC. Risk of melanoma in people with HIV\/AIDS in the pre- and post-HAART eras: a systematic review and meta-analysis of cohort studies. PLoS ONE. 2014;9:e95096. https:\/\/doi.org\/10.1371\/journal.pone.0095096.","journal-title":"PLoS ONE"},{"key":"3453_CR5","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","volume":"35","author":"TS Uldrick","year":"2017","unstructured":"Uldrick TS, Ison G, Rudek MA, et al. Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV working group. J Clin Oncol. 2017;35:3774\u201380. https:\/\/doi.org\/10.1200\/JCO.2017.73.7338.","journal-title":"J Clin Oncol"},{"key":"3453_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0771-1","volume":"7","author":"NJ Shah","year":"2019","unstructured":"Shah NJ, Al-Shbool G, Blackburn M, et al. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis\u00a0B, or hepatitis\u00a0C viral infection. J Immunother Cancer. 2019;7:353. https:\/\/doi.org\/10.1186\/s40425-019-0771-1.","journal-title":"J Immunother Cancer"},{"key":"3453_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1200\/JOP.19.00754","volume":"16","author":"IH Sahin","year":"2020","unstructured":"Sahin IH, Kane SR, Brutcher E, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer living with HIV: a perspective on recent progress and future needs. JCO Oncol Pract. 2020;16:319\u201325. https:\/\/doi.org\/10.1200\/JOP.19.00754.","journal-title":"JCO Oncol Pract"},{"key":"3453_CR8","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/jamaoncol.2020.0465","volume":"6","author":"M Gonzalez-Cao","year":"2020","unstructured":"Gonzalez-Cao M, Mor\u00e1n T, Dalmau J, et al. Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection: the phase\u00a02 DURVAST study. JAMA Oncol. 2020;6:1063\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0465.","journal-title":"JAMA Oncol"},{"key":"3453_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009728","volume":"12","author":"L Assoumou","year":"2024","unstructured":"Assoumou L, Bald\u00e9 R, Katlama C, et al. Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study. J Immunother Cancer. 2024;12:e009728. https:\/\/doi.org\/10.1136\/jitc-2024-009728.","journal-title":"J Immunother Cancer"},{"key":"3453_CR10","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","volume":"5","author":"MR Cook","year":"2019","unstructured":"Cook MR, Kim C. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review. JAMA Oncol. 2019;5:1049\u201354. https:\/\/doi.org\/10.1001\/jamaoncol.2018.6737.","journal-title":"JAMA Oncol"},{"key":"3453_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006947","volume":"11","author":"AC Pavlick","year":"2023","unstructured":"Pavlick AC, Ariyan CE, Buchbinder EI, et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. J Immunother Cancer. 2023;11:e006947. https:\/\/doi.org\/10.1136\/jitc-2023-006947.","journal-title":"J Immunother Cancer"},{"key":"3453_CR12","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1001\/jama.2011.1592","volume":"306","author":"EA Engels","year":"2011","unstructured":"Engels EA, Pfeiffer RM, Fraumeni JF, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306:1891\u2013901. https:\/\/doi.org\/10.1001\/jama.2011.1592.","journal-title":"JAMA"},{"key":"3453_CR13","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1200\/JCO.2013.49.2314","volume":"32","author":"EJ Lipson","year":"2014","unstructured":"Lipson EJ, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol. 2014;32:e69-71. https:\/\/doi.org\/10.1200\/JCO.2013.49.2314.","journal-title":"J Clin Oncol"},{"key":"3453_CR14","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMc1509268","volume":"374","author":"EJ Lipson","year":"2016","unstructured":"Lipson EJ, Bagnasco SM, Moore J, et al. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med. 2016;374:896\u20138. https:\/\/doi.org\/10.1056\/NEJMc1509268.","journal-title":"N Engl J Med"},{"key":"3453_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0585-1","volume":"7","author":"N Abdel-Wahab","year":"2019","unstructured":"Abdel-Wahab N, Safa H, Abudayyeh A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer. 2019;7:106. https:\/\/doi.org\/10.1186\/s40425-019-0585-1.","journal-title":"J Immunother Cancer"},{"key":"3453_CR16","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.jaad.2019.07.005","volume":"82","author":"J Fisher","year":"2020","unstructured":"Fisher J, Zeitouni N, Fan W, Samie FH. Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review. J Am Acad Dermatol. 2020;82:1490\u2013500. https:\/\/doi.org\/10.1016\/j.jaad.2019.07.005.","journal-title":"J Am Acad Dermatol"},{"key":"3453_CR17","doi-asserted-by":"publisher","first-page":"1284740","DOI":"10.3389\/frtra.2023.1284740","volume":"2","author":"S Ji","year":"2023","unstructured":"Ji S, Liu H, Pachella L, Stephenson RD, Groisberg R, Weiss SA. Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies. Front Transplant. 2023;2:1284740. https:\/\/doi.org\/10.3389\/frtra.2023.1284740.","journal-title":"Front Transplant"},{"key":"3453_CR18","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1038\/s41375-021-01193-6","volume":"35","author":"RW Merryman","year":"2021","unstructured":"Merryman RW, Castagna L, Giordano L, et al. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021;35:2672\u201383. https:\/\/doi.org\/10.1038\/s41375-021-01193-6.","journal-title":"Leukemia"},{"key":"3453_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001289","author":"B Moeckli","year":"2025","unstructured":"Moeckli B, Wassmer C-H, El Hajji S, et al. Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: an international retrospective cohort study. Hepatology. 2025. https:\/\/doi.org\/10.1097\/HEP.0000000000001289.","journal-title":"Hepatology"},{"key":"3453_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11523-025-01127-7","volume":"20","author":"M Shatila","year":"2025","unstructured":"Shatila M, Machado AP, Shah J, et al. Checkpoint inhibition prior to stem cell transplantation increases the risk of inflammatory adverse events. Target Oncol. 2025;20:329\u201337. https:\/\/doi.org\/10.1007\/s11523-025-01127-7.","journal-title":"Target Oncol"},{"key":"3453_CR21","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1634\/theoncologist.2019-0659","volume":"25","author":"V Kumar","year":"2020","unstructured":"Kumar V, Shinagare AB, Rennke HG, et al. The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature. Oncologist. 2020;25:505\u201314. https:\/\/doi.org\/10.1634\/theoncologist.2019-0659.","journal-title":"Oncologist"},{"key":"3453_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0054-4","volume":"3","author":"M Cecchini","year":"2015","unstructured":"Cecchini M, Sznol M, Seropian S. Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant. J Immunother Cancer. 2015;3:10. https:\/\/doi.org\/10.1186\/s40425-015-0054-4.","journal-title":"J Immunother Cancer"},{"key":"3453_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","volume":"25","author":"A Ijaz","year":"2019","unstructured":"Ijaz A, Khan AY, Malik SU, et al. Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant. 2019;25:94\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2018.08.028.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3453_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJMoa1601202","volume":"375","author":"MS Davids","year":"2016","unstructured":"Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375:143\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1601202.","journal-title":"N Engl J Med"},{"key":"3453_CR25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/bjh.19007","volume":"203","author":"P Apostolova","year":"2023","unstructured":"Apostolova P, Kreutmair S, Toffalori C, et al. Phase\u00a0II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response. Br J Haematol. 2023;203:264\u201381. https:\/\/doi.org\/10.1111\/bjh.19007.","journal-title":"Br J Haematol"},{"key":"3453_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001664","volume":"9","author":"M Gonzalez-Cao","year":"2021","unstructured":"Gonzalez-Cao M, Puertolas T, Riveiro M, et al. Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). J Immunother Cancer. 2021;9:e001664. https:\/\/doi.org\/10.1136\/jitc-2020-001664.","journal-title":"J Immunother Cancer"},{"key":"3453_CR27","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","volume":"39","author":"AA Sarnaik","year":"2021","unstructured":"Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol. 2021;39:2656\u201366. https:\/\/doi.org\/10.1200\/JCO.21.00612.","journal-title":"J Clin Oncol"},{"key":"3453_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008735","volume":"12","author":"A Betof Warner","year":"2024","unstructured":"Betof Warner A, Hamid O, Komanduri K, et al. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. J Immunother Cancer. 2024;12:e008735. https:\/\/doi.org\/10.1136\/jitc-2023-008735.","journal-title":"J Immunother Cancer"},{"key":"3453_CR29","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6911a2","author":"A MacNeil","year":"2020","unstructured":"MacNeil A. Global epidemiology of tuberculosis and progress toward meeting global targets \u2014 worldwide, 2018. MMWR Morb Mortal Wkly Rep. 2020. https:\/\/doi.org\/10.15585\/mmwr.mm6911a2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"3453_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat2702","volume":"11","author":"DL Barber","year":"2019","unstructured":"Barber DL, Sakai S, Kudchadkar RR, et al. Tuberculosis following PD-1 blockade for cancer immunotherapy. Sci Transl Med. 2019;11:eaat2702. https:\/\/doi.org\/10.1126\/scitranslmed.aat2702.","journal-title":"Sci Transl Med"},{"key":"3453_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005667","volume":"12","author":"S Sakai","year":"2016","unstructured":"Sakai S, Kauffman KD, Sallin MA, et al. CD4 T\u00a0cell-derived IFN-\u03b3 plays a minimal role in control of pulmonary Mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease. PLoS Pathog. 2016;12:e1005667. https:\/\/doi.org\/10.1371\/journal.ppat.1005667.","journal-title":"PLoS Pathog"},{"key":"3453_CR32","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.3389\/fimmu.2018.02094","volume":"9","author":"AJ Olive","year":"2018","unstructured":"Olive AJ, Sassetti CM. Tolerating the unwelcome guest; how the host withstands persistent Mycobacterium tuberculosis. Front Immunol. 2018;9:2094. https:\/\/doi.org\/10.3389\/fimmu.2018.02094.","journal-title":"Front Immunol"},{"key":"3453_CR33","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.52668","volume":"9","author":"LB Tezera","year":"2020","unstructured":"Tezera LB, Bielecka MK, Ogongo P, et al. Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-\u03b1. Elife. 2020;9:e52668. https:\/\/doi.org\/10.7554\/eLife.52668.","journal-title":"Elife"},{"key":"3453_CR34","doi-asserted-by":"publisher","DOI":"10.21037\/cco-23-153","volume":"13","author":"S Hirano","year":"2024","unstructured":"Hirano S, Takahashi H, Nakamura S, et al. A case of pulmonary tuberculosis that developed during nivolumab and ipilimumab treatment for pulmonary adenocarcinoma that recurred two months after completion of anti-tuberculous treatment. Chin Clin Oncol. 2024;13:43. https:\/\/doi.org\/10.21037\/cco-23-153.","journal-title":"Chin Clin Oncol"},{"key":"3453_CR35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12348-023-00374-x","volume":"13","author":"ML Murphy","year":"2023","unstructured":"Murphy ML, Rogers D. Tuberculosis reactivation demonstrated by choroiditis and inflammatory choroidal neovascular membrane in a patient treated with immune checkpoint inhibitors for malignant mucosal melanoma. J Ophthalmic Inflamm Infect. 2023;13:54. https:\/\/doi.org\/10.1186\/s12348-023-00374-x.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"3453_CR36","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.jinf.2017.03.012","volume":"74","author":"DF Simonsen","year":"2017","unstructured":"Simonsen DF, Farkas DK, Horsburgh CR, Thomsen RW, S\u00f8rensen HT. Increased risk of active tuberculosis after cancer diagnosis. J Infect. 2017;74:590\u20138. https:\/\/doi.org\/10.1016\/j.jinf.2017.03.012.","journal-title":"J Infect"},{"key":"3453_CR37","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/thoraxjnl-2021-217575","volume":"77","author":"J Zhu","year":"2022","unstructured":"Zhu J, He Z, Liang D, Yu X, Qiu K, Wu J. Pulmonary tuberculosis associated with immune checkpoint inhibitors: a pharmacovigilance study. Thorax. 2022;77:721\u20133. https:\/\/doi.org\/10.1136\/thoraxjnl-2021-217575.","journal-title":"Thorax"},{"key":"3453_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa126","volume":"7","author":"K Fujita","year":"2020","unstructured":"Fujita K, Yamamoto Y, Kanai O, et al. Incidence of active tuberculosis in lung cancer patients receiving immune checkpoint inhibitors. Open Forum Infect Dis. 2020;7:ofaa126. https:\/\/doi.org\/10.1093\/ofid\/ofaa126.","journal-title":"Open Forum Infect Dis"},{"key":"3453_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0717-7","volume":"7","author":"A Anastasopoulou","year":"2019","unstructured":"Anastasopoulou A, Ziogas DC, Samarkos M, Kirkwood JM, Gogas H. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J Immunother Cancer. 2019;7:239. https:\/\/doi.org\/10.1186\/s40425-019-0717-7.","journal-title":"J Immunother Cancer"},{"key":"3453_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.727220","volume":"13","author":"K Liu","year":"2022","unstructured":"Liu K, Wang D, Yao C, et al. Increased tuberculosis incidence due to immunotherapy based on PD-1 and PD-L1 blockade: a systematic review and meta-analysis. Front Immunol. 2022;13:727220. https:\/\/doi.org\/10.3389\/fimmu.2022.727220.","journal-title":"Front Immunol"},{"key":"3453_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002960","volume":"9","author":"S Bae","year":"2021","unstructured":"Bae S, Kim Y-J, Kim M, et al. Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study. J Immunother Cancer. 2021;9:e002960. https:\/\/doi.org\/10.1136\/jitc-2021-002960.","journal-title":"J Immunother Cancer"},{"key":"3453_CR42","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1007\/s00262-022-03198-1","volume":"71","author":"K Fujita","year":"2022","unstructured":"Fujita K, Elkington P, Redelman-Sidi G, et al. Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: a prospective cohort study. Cancer Immunol Immunother. 2022;71:2757\u201364. https:\/\/doi.org\/10.1007\/s00262-022-03198-1.","journal-title":"Cancer Immunol Immunother"},{"key":"3453_CR43","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1093\/oncolo\/oyad340","volume":"29","author":"H-W Chen","year":"2024","unstructured":"Chen H-W, Kuo Y-W, Chen C-Y, et al. Increased tuberculosis reactivation risk in patients receiving immune checkpoint inhibitor-based therapy. Oncologist. 2024;29:e498-506. https:\/\/doi.org\/10.1093\/oncolo\/oyad340.","journal-title":"Oncologist"},{"key":"3453_CR44","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-21-1283","volume":"27","author":"X Bai","year":"2021","unstructured":"Bai X, Hu J, Betof Warner A, et al. Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy. Clin Cancer Res. 2021;27:5993\u20136000. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1283.","journal-title":"Clin Cancer Res"},{"key":"3453_CR45","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1002\/cncr.31629","volume":"124","author":"AT Faje","year":"2018","unstructured":"Faje AT, Lawrence D, Flaherty K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124:3706\u201314. https:\/\/doi.org\/10.1002\/cncr.31629.","journal-title":"Cancer"},{"key":"3453_CR46","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1001\/jama.2023.3954","volume":"329","author":"DE Jonas","year":"2023","unstructured":"Jonas DE, Riley SR, Lee LC, et al. Screening for latent tuberculosis infection in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2023;329:1495\u2013509. https:\/\/doi.org\/10.1001\/jama.2023.3954.","journal-title":"JAMA"},{"key":"3453_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5:95. https:\/\/doi.org\/10.1186\/s40425-017-0300-z.","journal-title":"J Immunother Cancer"},{"key":"3453_CR48","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27:559\u201374. https:\/\/doi.org\/10.1093\/annonc\/mdv623.","journal-title":"Ann Oncol"},{"key":"3453_CR49","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","volume":"380","author":"S Swindells","year":"2019","unstructured":"Swindells S, Ramchandani R, Gupta A, et al. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019;380:1001\u201311. https:\/\/doi.org\/10.1056\/NEJMoa1806808.","journal-title":"N Engl J Med"},{"key":"3453_CR50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1164\/rccm.202410-2096ST","volume":"211","author":"JJ Saukkonen","year":"2025","unstructured":"Saukkonen JJ, Duarte R, Munsiff SS, et al. Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: an official ATS\/CDC\/ERS\/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2025;211:15\u201333. https:\/\/doi.org\/10.1164\/rccm.202410-2096ST.","journal-title":"Am J Respir Crit Care Med"},{"key":"3453_CR51","doi-asserted-by":"publisher","first-page":"7423","DOI":"10.2147\/OTT.S178246","volume":"11","author":"W He","year":"2018","unstructured":"He W, Zhang X, Li W, et al. Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report. OncoTargets Ther. 2018;11:7423\u20137. https:\/\/doi.org\/10.2147\/OTT.S178246.","journal-title":"OncoTargets Ther"},{"key":"3453_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06845-7","volume":"21","author":"K-S Lau","year":"2021","unstructured":"Lau K-S, Cheung BM-F, Lam K-O, et al. Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report. BMC Infect Dis. 2021;21:1148. https:\/\/doi.org\/10.1186\/s12879-021-06845-7.","journal-title":"BMC Infect Dis"},{"key":"3453_CR53","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.53203","volume":"16","author":"S Kikuta","year":"2024","unstructured":"Kikuta S, Abe Y, Shinozaki K, Seki N, Kusukawa J. Pulmonary tuberculosis following immune checkpoint inhibitor treatment for recurrent maxillary squamous cell carcinoma. Cureus. 2024;16:e53203. https:\/\/doi.org\/10.7759\/cureus.53203.","journal-title":"Cureus"},{"key":"3453_CR54","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1111\/j.1471-0528.2012.03475.x","volume":"119","author":"YY Lee","year":"2012","unstructured":"Lee YY, Roberts CL, Dobbins T, et al. Incidence and outcomes of pregnancy-associated cancer in Australia, 1994-2008: a population-based linkage study. BJOG. 2012;119:1572\u201382. https:\/\/doi.org\/10.1111\/j.1471-0528.2012.03475.x.","journal-title":"BJOG"},{"key":"3453_CR55","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1111\/j.1468-3083.2012.04550.x","volume":"27","author":"MP Rodero","year":"2013","unstructured":"Rodero MP, Prignon A, Avril MF, Boitier F, Aractingi S, Khosrotehrani K. Increase lymphangiogenesis in melanoma during pregnancy: correlation with the prolactin signalling pathway. J Eur Acad Dermatol Venereol. 2013;27:e144-145. https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04550.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3453_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102356","volume":"104","author":"A Khazzaka","year":"2022","unstructured":"Khazzaka A, Rassy E, Sleiman Z, Boussios S, Pavlidis N. Systematic review of fetal and placental metastases among pregnant patients with cancer. Cancer Treat Rev. 2022;104:102356. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102356.","journal-title":"Cancer Treat Rev"},{"key":"3453_CR57","doi-asserted-by":"publisher","DOI":"10.2217\/mmt-2020-0007","volume":"7","author":"E Zelin","year":"2020","unstructured":"Zelin E, Conforti C, Giuffrida R, Deinlein T, di Meo N, Zalaudek I. Melanoma in pregnancy: certainties unborn. Melanoma Manag. 2020;7:MMT48. https:\/\/doi.org\/10.2217\/mmt-2020-0007.","journal-title":"Melanoma Manag"},{"key":"3453_CR58","doi-asserted-by":"publisher","unstructured":"Wiedemann SV, M\u00fcller V, Toth B, et al. CLAUDIUS Study: Risk of materno-fetal transmission of melanoma cells in pregnant women with high grade melanoma \u2013 A retrospective multicenter study and literature review. EJC Skin Cancer. 2023;1:100005. https:\/\/doi.org\/10.1016\/j.ejcskn.2023.100005.","DOI":"10.1016\/j.ejcskn.2023.100005"},{"key":"3453_CR59","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.5625","volume":"7","author":"P Gougis","year":"2024","unstructured":"Gougis P, Hamy A-S, Jochum F, et al. Immune checkpoint inhibitor use during pregnancy and outcomes in pregnant individuals and newborns. JAMA Netw Open. 2024;7:e245625. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.5625.","journal-title":"JAMA Netw Open"},{"key":"3453_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100262","volume":"6","author":"A Andrikopoulou","year":"2021","unstructured":"Andrikopoulou A, Korakiti AM, Apostolidou K, Dimopoulos MA, Zagouri F. Immune checkpoint inhibitor administration during pregnancy: a case series. ESMO Open. 2021;6:100262. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100262.","journal-title":"ESMO Open"},{"key":"3453_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.854967","volume":"13","author":"K Zhang","year":"2022","unstructured":"Zhang K, Kong X, Li Y, Wang Z, Zhang L, Xuan L. PD-1\/PD-L1 inhibitors in patients with preexisting autoimmune diseases. Front Pharmacol. 2022;13:854967. https:\/\/doi.org\/10.3389\/fphar.2022.854967.","journal-title":"Front Pharmacol"},{"key":"3453_CR62","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1002\/cncr.32326","volume":"125","author":"M Pantuck","year":"2019","unstructured":"Pantuck M, McDermott D, Drakaki A. To treat or not to treat: patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease. Cancer. 2019;125:3506\u201313. https:\/\/doi.org\/10.1002\/cncr.32326.","journal-title":"Cancer"},{"key":"3453_CR63","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejca.2016.12.017","volume":"74","author":"M Donia","year":"2017","unstructured":"Donia M, Kimper-Karl ML, H\u00f8yer KL, Bastholt L, Schmidt H, Svane IM. The majority of patients with metastatic melanoma are not represented in pivotal phase\u00a0III immunotherapy trials. Eur J Cancer. 2017;74:89\u201395. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.017.","journal-title":"Eur J Cancer"},{"key":"3453_CR64","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12885-018-4051-0","volume":"18","author":"Q Ma","year":"2018","unstructured":"Ma Q, Shilkrut M, Zhao Z, Li M, Batty N, Barber B. Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data. BMC Cancer. 2018;18:145. https:\/\/doi.org\/10.1186\/s12885-018-4051-0.","journal-title":"BMC Cancer"},{"key":"3453_CR65","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3390\/cancers14040991","volume":"14","author":"F Scatozza","year":"2022","unstructured":"Scatozza F, Facchiano A. Expression of autoimmunity-related genes in melanoma. Cancers. 2022;14:991. https:\/\/doi.org\/10.3390\/cancers14040991.","journal-title":"Cancers"},{"key":"3453_CR66","doi-asserted-by":"publisher","first-page":"7457","DOI":"10.1002\/cam4.4239","volume":"10","author":"N Gulati","year":"2021","unstructured":"Gulati N, Celen A, Johannet P, et al. Preexisting immune-mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors. Cancer Med. 2021;10:7457\u201365. https:\/\/doi.org\/10.1002\/cam4.4239.","journal-title":"Cancer Med"},{"key":"3453_CR67","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1136\/ard-2022-222186","volume":"81","author":"L Pla\u00e7ais","year":"2022","unstructured":"Pla\u00e7ais L, Dalle S, Dereure O, et al. Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study. Ann Rheum Dis. 2022;81:1445\u201352. https:\/\/doi.org\/10.1136\/ard-2022-222186.","journal-title":"Ann Rheum Dis"},{"key":"3453_CR68","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.45596","volume":"5","author":"AS Watson","year":"2022","unstructured":"Watson AS, Goutam S, Stukalin I, et al. Association of immune-related adverse events, hospitalization, and therapy resumption with survival among patients with metastatic melanoma receiving single-agent or combination immunotherapy. JAMA Netw Open. 2022;5:e2245596. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.45596.","journal-title":"JAMA Netw Open"},{"key":"3453_CR69","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00262-018-2134-z","volume":"67","author":"KC K\u00e4hler","year":"2018","unstructured":"K\u00e4hler KC, Eigentler TK, Gesierich A, et al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunol Immunother. 2018;67:825\u201334. https:\/\/doi.org\/10.1007\/s00262-018-2134-z.","journal-title":"Cancer Immunol Immunother"},{"key":"3453_CR70","doi-asserted-by":"publisher","first-page":"641","DOI":"10.7326\/M20-3419","volume":"174","author":"MK van der Kooij","year":"2021","unstructured":"van der Kooij MK, Suijkerbuijk KPM, Aarts MJB, et al. Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease\u202f: a cohort study. Ann Intern Med. 2021;174:641\u20138. https:\/\/doi.org\/10.7326\/M20-3419.","journal-title":"Ann Intern Med"},{"key":"3453_CR71","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/art.41068","volume":"71","author":"A Tison","year":"2019","unstructured":"Tison A, Qu\u00e9r\u00e9 G, Misery L, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol. 2019;71:2100\u201311. https:\/\/doi.org\/10.1002\/art.41068.","journal-title":"Arthritis Rheumatol"},{"key":"3453_CR72","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s12885-024-12256-z","volume":"24","author":"X Liu","year":"2024","unstructured":"Liu X, Li S, Ke L, Cui H. Immune checkpoint inhibitors in cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis. BMC Cancer. 2024;24:490. https:\/\/doi.org\/10.1186\/s12885-024-12256-z.","journal-title":"BMC Cancer"},{"key":"3453_CR73","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2:234\u201340. https:\/\/doi.org\/10.1001\/jamaoncol.2015.4368.","journal-title":"JAMA Oncol"},{"key":"3453_CR74","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28:368\u201376. https:\/\/doi.org\/10.1093\/annonc\/mdw443.","journal-title":"Ann Oncol"},{"key":"3453_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002121","volume":"9","author":"LJ Brown","year":"2021","unstructured":"Brown LJ, Weppler A, Bhave P, et al. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. J Immunother Cancer. 2021;9:e002121. https:\/\/doi.org\/10.1136\/jitc-2020-002121.","journal-title":"J Immunother Cancer"},{"key":"3453_CR76","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073\u2013126. https:\/\/doi.org\/10.1200\/JCO.21.01440.","journal-title":"J Clin Oncol"},{"key":"3453_CR77","doi-asserted-by":"publisher","first-page":"TPS3158","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3158","volume":"38","author":"EE Ileana Dumbrava","year":"2020","unstructured":"Ileana Dumbrava EE, Suarez-Almazor ME, Painter J, et al. A phase\u00a0Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO). J Clin Oncol. 2020;38:TPS3158\u2013TPS3158. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.TPS3158.","journal-title":"J Clin Oncol"},{"key":"3453_CR78","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/archdermatol.2010.2","volume":"146","author":"PT Bradford","year":"2010","unstructured":"Bradford PT, Freedman DM, Goldstein AM, Tucker MA. Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol. 2010;146:265\u201372. https:\/\/doi.org\/10.1001\/archdermatol.2010.2.","journal-title":"Arch Dermatol"},{"key":"3453_CR79","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1186\/s12885-021-08845-x","volume":"21","author":"G Zheng","year":"2021","unstructured":"Zheng G, Chattopadhyay S, Sundquist K, et al. Types of second primary cancer influence overall survival in cutaneous melanoma. BMC Cancer. 2021;21:1123. https:\/\/doi.org\/10.1186\/s12885-021-08845-x.","journal-title":"BMC Cancer"},{"key":"3453_CR80","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/bjd.16270","volume":"178","author":"G Salomon","year":"2018","unstructured":"Salomon G, Maza A, Boulinguez S, et al. Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum. Br J Dermatol. 2018;178:1199\u2013203. https:\/\/doi.org\/10.1111\/bjd.16270.","journal-title":"Br J Dermatol"},{"key":"3453_CR81","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1080\/0284186X.2022.2109425","volume":"61","author":"A Hennemann","year":"2022","unstructured":"Hennemann A, Collonge Rame MA, Puzenat E, et al. Efficacy of pembrolizumab in a patient with xeroderma pigmentosum variant and advanced cutaneous squamous-cell carcinoma. Acta Oncol. 2022;61:1140\u20132. https:\/\/doi.org\/10.1080\/0284186X.2022.2109425.","journal-title":"Acta Oncol"},{"key":"3453_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0129-x","volume":"4","author":"ME Marmarelis","year":"2016","unstructured":"Marmarelis ME, Davis MR, Sethi NS, et al. Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma. J Immunother Cancer. 2016;4:26. https:\/\/doi.org\/10.1186\/s40425-016-0129-x.","journal-title":"J Immunother Cancer"},{"key":"3453_CR83","volume":"4","author":"S Unlu","year":"2021","unstructured":"Unlu S, Grant MJ, Gettinger S, Adeniran A, Kluger HM. Prolonged complete response of early stage primary adenocarcinoma of the lung to nivolumab monotherapy. Clin Oncol Case Rep. 2021;4:157.","journal-title":"Clin Oncol Case Rep"},{"key":"3453_CR84","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3747\/co.27.5371","volume":"27","author":"I Landego","year":"2020","unstructured":"Landego I, Hewitt D, Hibbert I, et al. PD-1 inhibition in malignant melanoma and lack of clinical response in chronic lymphocytic leukemia in the same patients: a case series. Curr Oncol. 2020;27:169\u201372. https:\/\/doi.org\/10.3747\/co.27.5371.","journal-title":"Curr Oncol"},{"issue":"1","key":"3453_CR85","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/CJI.0000000000000345","volume":"44","author":"JW Smithy","year":"2021","unstructured":"Smithy JW, Pianko MJ, Maher C, et al. Checkpoint blockade in melanoma patients with underlying chronic lymphocytic leukemia. J Immunother. 2021;44(1):9\u201315. https:\/\/doi.org\/10.1097\/CJI.0000000000000345.","journal-title":"J Immunother"},{"key":"3453_CR86","doi-asserted-by":"publisher","first-page":"1606599","DOI":"10.3389\/fonc.2025.1606599","volume":"15","author":"S Tapiavala","year":"2025","unstructured":"Tapiavala S, Luo C, Shenouda M, Patel V, Davis AA. Reporting of immune-related adverse events in US Food and Drug Administration approvals of immune checkpoint inhibitors. Front Oncol. 2025;15:1606599. https:\/\/doi.org\/10.3389\/fonc.2025.1606599.","journal-title":"Front Oncol"},{"key":"3453_CR87","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1003466.","journal-title":"N Engl J Med"},{"key":"3453_CR88","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1412082.","journal-title":"N Engl J Med"},{"key":"3453_CR89","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1503093.","journal-title":"N Engl J Med"},{"key":"3453_CR90","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1709684.","journal-title":"N Engl J Med"},{"key":"3453_CR91","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","volume":"395","author":"R Gutzmer","year":"2020","unstructured":"Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet. 2020;395:1835\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(20)30934-X.","journal-title":"Lancet"},{"key":"3453_CR92","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab\nin untreated advanced melanoma. N Engl J Med. 2022;386:24\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2109970","journal-title":"N Engl J Med"},{"key":"3453_CR93","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200239","volume":"2","author":"GV Long","year":"2023","unstructured":"Long GV, Stephen Hodi F, Lipson EJ, et al. Overall survival and response with nivolumab and relatlimab in advanced melanoma. NEJM Evid. 2023;2:EVIDoa2200239. https:\/\/doi.org\/10.1056\/EVIDoa2200239.","journal-title":"NEJM Evid"},{"key":"3453_CR94","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RHI Andtbacka","year":"2015","unstructured":"Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:2780\u20138. https:\/\/doi.org\/10.1200\/JCO.2014.58.3377","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3453_CR95","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1200\/JCO.22.00343","volume":"41","author":"JA Chesney","year":"2023","unstructured":"Chesney JA, Ribas A, Long GV, et al. Randomized, double-blind, placebo-controlled, global phase\u00a0III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J Clin Oncol. 2023;41:528\u201340. https:\/\/doi.org\/10.1200\/JCO.22.00343.","journal-title":"J Clin Oncol"},{"key":"3453_CR96","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"J Chesney","year":"2022","unstructured":"Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022;10:e005755. https:\/\/doi.org\/10.1136\/jitc-2022-005755.","journal-title":"J Immunother Cancer"},{"key":"3453_CR97","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1200\/JCO.22.02459","volume":"41","author":"T El Zarif","year":"2023","unstructured":"El Zarif T, Nassar AH, Adib E, et al. Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: a real-world report from the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. J Clin Oncol. 2023;41:3712\u201323. https:\/\/doi.org\/10.1200\/JCO.22.02459.","journal-title":"J Clin Oncol"},{"key":"3453_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","volume":"69","author":"TR Sterling","year":"2020","unstructured":"Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020;69:1\u201311. https:\/\/doi.org\/10.15585\/mmwr.rr6901a1.","journal-title":"MMWR Recomm Rep"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03453-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03453-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03453-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:02:55Z","timestamp":1771268575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03453-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":98,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3453"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03453-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bryan L. Peacker, Jonathan C. Hwang, and Rebecca I. Hartman have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}